For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.
Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.